These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 11355558

  • 1. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
    Thakur CP, Dedet JP, Narain S, Pratlong F.
    Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
    [Abstract] [Full Text] [Related]

  • 2. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antimony susceptible Leishmania donovani: evidence from in vitro drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.
    Ghosh S, Verma A, Kumar D, Deep DK, Ramesh V, Salotra P, Singh R.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0402623. PubMed ID: 38712926
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
    Singh S, Kumar J, Singh R, Dwivedi SN.
    Int J Infect Dis; 2000 Jun 04; 4(4):203-8. PubMed ID: 11231183
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
    Mishra J, Madhubala R, Singh S.
    Parasitol Res; 2013 Mar 04; 112(3):1001-9. PubMed ID: 23242321
    [Abstract] [Full Text] [Related]

  • 18. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S, Mishra J, Gupta AK, Singh A, Shankar P, Singh S.
    Parasit Vectors; 2017 Jan 31; 10(1):49. PubMed ID: 28137296
    [Abstract] [Full Text] [Related]

  • 19. Genetic markers for antimony resistant clinical isolates differentiation from Indian Kala-azar.
    Khanra S, Sarraf NR, Das S, Das AK, Roy S, Manna M.
    Acta Trop; 2016 Dec 31; 164():177-184. PubMed ID: 27629023
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.